Structure-Activity and Structure-Property Relationship and Exploratory in Vivo Evaluation of the Nanomolar Keap1-Nrf2 Protein-Protein Interaction Inhibitor

Journal of Medicinal Chemistry

Volumn 58, Issue 16, 2015, Pages 6410-6421

  Jiang, Zheng Yu ^a   Xu, Li Li ^a   Lu, Meng Chen ^a   Chen, Zhi Yun ^a   Yuan, Zhen Wei ^a   Xu, Xiao Li ^a   Guo, Xiao Ke ^a   Zhang, Xiao Jin ^a   Sun, Hao Peng ^a   You, Qi Dong ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2,2' [(2 METHOXY 1,4 PHENYLENE)BIS[[(4 METHOXYPHENYL)SULFONYL]AZANEDIYL]]DIACETIC ACID; 2,2' [(2 METHYL 1,4 PHENYLENE)BIS[[(4 METHOXYPHENYL)SULFONYL]AZANEDIYL]]DIACETIC ACID; 2,2' [(2,5 DIMETHYL 1,4 PHENYLENE)BIS[[(4 METHOXYPHENYL)SULFONYL]AZANEDIYL]]DIACETIC ACID; 2,2' [1,4 PHENYLENEBIS(TOSYLAZANEDIYL)]DIACETIC ACID; 2,2' [NAPHTHALENE 1,4 DIYLBIS(TOSYLAZANEDIYL)]DIACETIC ACID; 2,2' [NAPHTHALENE 1,4 DIYLBIS[(NAPHTHALEN 2 YLSULFONYL)AZANEDIYL]]DIACETIC ACID; 2,2' [NAPHTHALENE 1,4 DIYLBIS[(PHENYLSULFONYL)AZANEDIYL]DIACETIC ACID; 2,2' [NAPHTHALENE 1,4 DIYLBIS[[(4 ACETAMIDOOPHENYL)SULFONYL]AZANEDIYL]]DIACETIC ACID; 2,2' [NAPHTHALENE 1,4 DIYLBIS[[(4 BROMOPHENYL)SULFONYL]AZANEDIYL]]DIACETIC ACID; 2,2' [NAPHTHALENE 1,4 DIYLBIS[[(4 CHLOROPHENYL)SULFONYL]AZANEDIYL]]DIACETIC ACID; 2,2' [NAPHTHALENE 1,4 DIYLBIS[[(4 FLUOROPHENYL)SULFONYL]AZANEDIYL]]DIACETIC ACID; 2,2' [NAPHTHALENE 1,4 DIYLBIS[[[4 (TERT BUTYL)PHENYL]SULFONYL]AZANEDIYL]]DIACETIC ACID; 2,2' [NAPHTHALENE 1,4 DIYLBIS[[[4 (TRIFLUOROMETHYL 2 YLSULFONYL)AZANEDIYL]]DIACETIC ACID; 2,2' [NAPHTHALENE 1,4 DIYLBIS[[[4 (TRIFLUOROMETHYL)PHENYL]SULFONYL]AZANEDIYL]]DIACETIC ACID; ANTIINFLAMMATORY AGENT; DEXAMETHASONE; DIETHYL 2,2' [1,4 PHENYLENEBIS[[(4 METHOXYPHENYL)SULFONYL]AZANEDIYL]]DIACETATE; DIETHYL 2,2' [NAPHTHALENE 1,4 DIYLBIS(TOSYLAZANEDIYL)]DIACETIC ACID; GAMMA INTERFERON; HEME OXYGENASE 1; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 6; KELCH LIKE ECH ASSOCIATED PROTEIN 1; PROTEIN INHIBITOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); SMALL INTERFERING RNA; TRANSCRIPTION FACTOR NRF2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; CYTOKINE; KEAP1 PROTEIN, HUMAN; LIPOPOLYSACCHARIDE; NFE2L2 PROTEIN, HUMAN; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN BINDING; SIGNAL PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG SYNTHESIS; FEMALE; GENE CONTROL; IN VIVO STUDY; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; PROTEIN PROTEIN INTERACTION; STRUCTURE ACTIVITY RELATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; C57BL MOUSE; CELL LINE; CHEMICAL STRUCTURE; DRUG EFFECTS; GENETICS; HUMAN; METABOLIC ACTIVATION; METABOLISM; SYNTHESIS;

ACTIVATION, METABOLIC; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL LINE; CYTOKINES; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED C57BL; MODELS, MOLECULAR; NF-E2-RELATED FACTOR 2; PROTEIN BINDING; RNA, SMALL INTERFERING; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84940483090     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b00185     Document Type: Article

References (28)

1. Kobayashi, M.; Yamamoto, M. Molecular mechanisms activating the Nrf2-Keap1 pathway of antioxidant gene regulation Antioxid. Redox Signaling 2005, 7, 385-94 10.1089/ars.2005.7.385
2. Stepkowski, T. M.; Kruszewski, M. K. Molecular cross-talk between the NRF2/KEAP1 signaling pathway, autophagy, and apoptosis Free Radical Biol. Med. 2011, 50, 1186-95 10.1016/j.freeradbiomed.2011.01.033
3. Taguchi, K.; Motohashi, H.; Yamamoto, M. Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution Genes to Cells 2011, 16, 123-140 10.1111/j.1365-2443.2010.01473.x
4. Wilson, A. J.; Kerns, J. K.; Callahan, J. F.; Moody, C. J. Keap calm, and carry on covalently J. Med. Chem. 2013, 56, 7463-76 10.1021/jm400224q
5. Magesh, S.; Chen, Y.; Hu, L. Small Molecule Modulators of Keap1-Nrf2-ARE Pathway as Potential Preventive and Therapeutic Agents Med. Res. Rev. 2012, 32, 687-726 10.1002/med.21257
6. Suzuki, T.; Motohashi, H.; Yamamoto, M. Toward clinical application of the Keap1-Nrf2 pathway Trends Pharmacol. Sci. 2013, 34, 340-346 10.1016/j.tips.2013.04.005
7. Cleasby, A.; Yon, J.; Day, P. J.; Richardson, C.; Tickle, I. J.; Williams, P. A.; Callahan, J. F.; Carr, R.; Concha, N.; Kerns, J. K.; Qi, H.; Sweitzer, T.; Ward, P.; Davies, T. G. Structure of the BTB Domain of Keap1 and Its Interaction with the Triterpenoid Antagonist CDDO PLoS One 2014, 9, e98896 10.1371/journal.pone.0098896
8. Hancock, R.; Bertrand, H. C.; Tsujita, T.; Naz, S.; El-Bakry, A.; Laoruchupong, J.; Hayes, J. D.; Wells, G. Peptide inhibitors of the Keap1-Nrf2 protein-protein interaction Free Radical Biol. Med. 2012, 52, 444-51 10.1016/j.freeradbiomed.2011.10.486
9. Steel, R.; Cowan, J.; Payerne, E.; O'Connell, M. A.; Searcey, M. Anti-inflammatory Effect of a Cell-Penetrating Peptide Targeting the Nrf2/Keap1 Interaction ACS Med. Chem. Lett. 2012, 3, 407-410 10.1021/ml300041g
10. Bowman, A. L.; Nikolovska-Coleska, Z.; Zhong, H.; Wang, S.; Carlson, H. A. Small molecule inhibitors of the MDM2-p53 interaction discovered by ensemble-based receptor models J. Am. Chem. Soc. 2007, 129, 12809-14 10.1021/ja073687x
11. Hu, L.; Magesh, S.; Chen, L.; Wang, L.; Lewis, T. A.; Chen, Y.; Khodier, C.; Inoyama, D.; Beamer, L. J.; Emge, T. J.; Shen, J.; Kerrigan, J. E.; Kong, A. N.; Dandapani, S.; Palmer, M.; Schreiber, S. L.; Munoz, B. Discovery of a small-molecule inhibitor and cellular probe of Keap1-Nrf2 protein-protein interaction Bioorg. Med. Chem. Lett. 2013, 23, 3039-43 10.1016/j.bmcl.2013.03.013
12. Jnoff, E.; Albrecht, C.; Barker, J. J.; Barker, O.; Beaumont, E.; Bromidge, S.; Brookfield, F.; Brooks, M.; Bubert, C.; Ceska, T.; Corden, V.; Dawson, G.; Duclos, S.; Fryatt, T.; Genicot, C.; Jigorel, E.; Kwong, J.; Maghames, R.; Mushi, I.; Pike, R.; Sands, Z. A.; Smith, M. A.; Stimson, C. C.; Courade, J. P. Binding mode and structure-activity relationships around direct inhibitors of the Nrf2-Keap1 complex ChemMedChem 2014, 9, 699-705 10.1002/cmdc.201300525
13. Marcotte, D.; Zeng, W.; Hus, J.-C.; McKenzie, A.; Hession, C.; Jin, P.; Bergeron, C.; Lugovskoy, A.; Enyedy, I.; Cuervo, H.; Wang, D.; Atmanene, C.; Roecklin, D.; Vecchi, M.; Vivat, V.; Kraemer, J.; Winkler, D.; Hong, V.; Chao, J.; Lukashev, M.; Silvian, L. Small molecules inhibit the interaction of Nrf2 and the Keap1 Kelch domain through a non-covalent mechanism Bioorg. Med. Chem. 2013, 21, 4011-4019 10.1016/j.bmc.2013.04.019
14. Sun, H.-P.; Jiang, Z.-Y.; Zhang, M.-Y.; Lu, M.-C.; Yang, T.-T.; Pan, Y.; Huang, H.-Z.; Zhang, X.-J.; You, Q.-d. Novel protein-protein interaction inhibitor of Nrf2-Keap1 discovered by structure-based virtual screening MedChemComm 2014, 5, 93-98 10.1039/C3MD00240C
15. Zhuang, C.; Narayanapillai, S.; Zhang, W.; Sham, Y. Y.; Xing, C. Rapid identification of Keap1-Nrf2 small-molecule inhibitors through structure-based virtual screening and hit-based substructure search J. Med. Chem. 2014, 57, 1121-6 10.1021/jm4017174
16. Jiang, Z.-Y.; Lu, M.-C.; Xu, L. L.; Yang, T.-T.; Xi, M.-Y.; Xu, X.-L.; Guo, X.-K.; Zhang, X.-J.; You, Q.-D.; Sun, H.-P. Discovery of Potent Keap1-Nrf2 Protein-Protein Interaction Inhibitor Based on Molecular Binding Determinants Analysis J. Med. Chem. 2014, 57, 2736-2745 10.1021/jm5000529
17. Jiang, Z.-Y.; Xu, L.-L.; Lu, M.-C.; Pan, Y.; Huang, H.-Z.; Zhang, X.-J.; Sun, H.-P.; You, Q.-D. Investigation of the intermolecular recognition mechanism between the E3 ubiquitin ligase Keap1 and substrate based on multiple substrates analysis J. Comput.-Aided Mol. Des. 2014, 28, 1233-1245 10.1007/s10822-014-9799-y
18. Shultz, M. D. Setting expectations in molecular optimizations: Strengths and limitations of commonly used composite parameters Bioorg. Med. Chem. Lett. 2013, 23 (21) 5980-91 10.1016/j.bmcl.2013.08.029
19. Rushworth, S. A.; MacEwan, D. J.; O'Connell, M. A. Lipopolysaccharide-Induced Expression of NAD(P)H:Quinone Oxidoreductase 1 and Heme Oxygenase-1 Protects against Excessive Inflammatory Responses in Human Monocytes J. Immunol. 2008, 181, 6730-6737 10.4049/jimmunol.181.10.6730
20. Akira, S.; Takeda, K. Toll-like receptor signalling Nat. Rev. Immunol. 2004, 4, 499-511 10.1038/nri1391
21. Asehnoune, K.; Strassheim, D.; Mitra, S.; Kim, J. Y.; Abraham, E. Involvement of reactive oxygen species in Toll-like receptor 4-dependent activation of NF-kappa B J. Immunol. 2004, 172, 2522-9 10.4049/jimmunol.172.4.2522
22. Auletta, J. J.; Alabran, J. L.; Kim, B. G.; Meyer, C. J.; Letterio, J. J. The synthetic triterpenoid, CDDO-Me, modulates the proinflammatory response to in vivo lipopolysaccharide challenge J. Interferon Cytokine Res. 2010, 30, 497-508 10.1089/jir.2009.0100
23. Avdeef, A.; Tsinman, O. Miniaturized Rotating Disk Intrinsic Dissolution Rate Measurement: Effects of Buffer Capacity in Comparisons to Traditional Wood's Apparatus Pharm. Res. 2008, 25, 2613-2627 10.1007/s11095-008-9679-z
24. Avdeef, A.; Bucher, J. J. Accurate measurements of the concentration of hydrogen ions with a glass electrode: calibrations using the Prideaux and other universal buffer solutions and a computer-controlled automatic titrator Anal. Chem. 1978, 50, 2137-2142 10.1021/ac50036a045
25. Zhang, X.; Li, X.; Sun, H.; Wang, X.; Zhao, L.; Gao, Y.; Liu, X.; Zhang, S.; Wang, Y.; Yang, Y.; Zeng, S.; Guo, Q.; You, Q. Garcinia Xanthones as Orally Active Antitumor Agents J. Med. Chem. 2013, 56, 276-292 10.1021/jm301593r
26. Avdeef, A.; Berger, C. M. pH-metric solubility.: 3. Dissolution titration template method for solubility determination Eur. J. Pharm. Sci. 2001, 14, 281-291 10.1016/S0928-0987(01)00190-7
27. Avdeef, A. pH-metric Solubility. 1. Solubility-pH Profiles from Bjerrum Plots. Gibbs Buffer and pKa in the Solid State Pharm. Pharmacol. Commun. 1998, 4, 165-178 10.1111/j.2042-7158.1998.tb00328.x
28. Xi, M. Y.; Jia, J. M.; Sun, H. P.; Sun, Z. Y.; Jiang, J. W.; Wang, Y. J.; Zhang, M. Y.; Zhu, J. F.; Xu, L. L.; Jiang, Z. Y.; Xue, X.; Ye, M.; Yang, X.; Gao, Y.; Tao, L.; Guo, X. K.; Xu, X. L.; Guo, Q. L.; Zhang, X. J.; Hu, R.; You, Q. D. 3-Aroylmethylene-2,3,6,7-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4(11bH)-ones as Potent Nrf2/ARE Inducers in Human Cancer Cells and AOM-DSS Treated Mice J. Med. Chem. 2013, 56, 7925-7938 10.1021/jm400944k